MXC on clear path to enter multi-million-dollar Australian medical cannabis market
Europe-based medicinal cannabis company, MGC Pharmaceuticals (ASX:MXC), today revealed that it has executed a binding definitive exclusive supply agreement with specialist pharmaceutical wholesaler and distributor, HL Pharma, to bring its adult epilepsy product, CannEpilTM, to the Australian market from early 2018.
This follows on from the signing of a heads of agreement (HoA) with HL Pharma, as announced at the beginning of the month.
This deal is set to generate considerable annual revenues for MXC, with the product delivering strong gross profit margins. MXC’s Pharma division plans to manufacture the product at its world-class Slovenian facility, which is currently undergoing GMP certification.
MXC now has a clear pathway for delivering the first MGC Pharmaceuticals medicinal cannabis products to the multi-million-dollar Australian market. The product will launch early next year, once HL Pharma has obtained all necessary approvals for importing the product.
MXC already has strong ties to Epilepsy Action Australia (EAA), with whom it is working closely to rapidly build an Australian patient market through an expanding network of authorised prescribing Australian doctors.
An initial group of at least five doctors have already formally registered interest in prescribing the product, and are currently in the process of applying for authorised prescriber status with Australian regulatory authorities.
MGC Pharmaceuticals is expected to generate around $1 million next year alone from a small starting pool of 100 registered patients. This has strong potential to increase, given the expansive Australian market.
The CannEpil product targets drug-resistant epilepsy (also known as refractory epilepsy), which accounts for around 30% of the 25,000 cases that are diagnosed in Australia each year.
More broadly, according to the EAA, around 25,000 people are diagnosed with epilepsy each year, and up to 240,000 Australians are currently living with epilepsy.
How much of this market MXC will be able to reach is yet to be determined so investors should seek professional financial advice if considering this stock for their portfolio.
The product will be made available to patients with an authorised doctor’s prescription for a regular retail price under A$800 – significantly lower than competing products currently on the market, making this an appealingly affordable option for patients.
HL Pharma has over 20 years of experience as a specialist supplier of unregistered pharmaceutical products (these are not registered with the Therapeutic Goods Agency (TGA), but are registered with other recognised pharmaceutical regulators) in Australia. It only sources products from registered suppliers with a pharmaceutical wholesale or manufacturing license and are registered with the Medicines and Health Regulatory Agency (MHRA) in the UK.
According to the terms of the agreement, HL Pharma is required to first work with MXC for provision of relevant products for distribution in the future within Australia before seeking out other potential suppliers.
Roby Zomer, MXC co-founder and CEO, said: “We now have a clear view on the pathway to the commencement of an Australian sales pipeline and revenue stream for our medical cannabis products which is a key milestone for our company and is further evidence of the strong momentum that we are building through the execution of revenue generating agreements.”
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.